Venlafaxine hydrochloride sustained-release tablet preparation and preparation method thereof

A technology for venlafaxine hydrochloride and sustained-release tablets, which is applied in the direction of pharmaceutical formulas, medical preparations containing no active ingredients, medical preparations containing active ingredients, etc., and can solve the problem of large fluctuations in blood drug concentration, large side effects, and rapid metabolism And other issues
CN101584674AInactive Publication Date: 2009-11-25上海医药科技发展有限公司
0 Cites 10 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
上海医药科技发展有限公司
Publication Date
2009-11-25
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a venlafaxine hydrochloride sustained-release tablet preparation which comprises venlafaxine hydrochloride, framework material, diluent, lubricant, adhesive and coating material. The experiments demonstrate that the venlafaxine hydrochloride sustained-release tablet achieves better sustained-release effect, can reduce the dosing frequency and is convenient for the patients to use. The invention also provides a preparation method thereof.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of pharmaceutical preparations, in particular to a novel antidepressant venlafaxine hydrochloride sustained-release tablet preparation and a preparation method thereof. Background technique

[0002] Venlafaxine is a novel phenethylamine derivative. Its mechanism of action is different from that of tricyclic antidepressants and newer selective serotonin reuptake inhibitors in that it exerts antidepressant effects through inhibition of norepinephrine and serotonin reuptake and weak inhibition of dopamine reuptake. Depressive effect, no inhibitory effect on monoamine oxidase, no affinity with cholinergic, histaminergic, adrenergic and other receptors, so there are no adverse reactions related to these receptors, such as sedation, dry mouth, constipation, urinary retention and blurred vision . Venlafaxine is a new type of antidepressant with rapid onset, good tolerance, and good short-term and long-term therapeutic effe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More